april 22 semaglutide GLP-1 agonists like and Tirzepatide are changing weight loss — but the full picture is rarely discussed. ❗️ This post breaks down what's often overlooked: muscle, bone health & the protocol Semaglutide: Shedding pounds, weighing risks

We begin with the scientific background tracing the incretin concept from early 20th-century experiments through the discovery of GLP-1 in the 1980s

This combination of a manageable safety profile and an ethical trial design that prioritizes patient outcomes is encouraging for future clinical adoption and real-world application

The study also developed reliable methods for detecting AOD9604 in biological samples, which has applications in sports anti-doping testing since growth hormone fragments have been misused by athletes seeking performance enhancement

Ocular side effects There is a reported increased risk of diabetic retinopathy with GLP-1 agonists, specifically semaglutide (Ozempic, Wegovy) as demonstrated by the SUSTAIN-6 trial (HR 1.76